Wells Fargo & Company Gt Biopharma, Inc. Transaction History

Wells Fargo & Company

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.22 - $0.28 $4 - $6	22 Added 0.01%	300,719 $78,000
Q3 2023 Nov 13, 2023	BUY	$0.24 - $0.35 $48,024 - $70,036	200,103 Added 198.92%	300,697 $72,000
Q2 2023 Aug 15, 2023	BUY	$0.22 - $0.55 $7 - $17	32 Added 0.03%	100,594 $31,000
Q1 2023 May 12, 2023	BUY	$0.46 - $1.05 $0 - $2	2 Added 0.0%	100,562 $55,000
Q4 2022 Feb 13, 2023	BUY	$0.89 - $58.2 $89,012 - $5.82 Million	100,014 Added 18317.58%	100,560 $89,000
Q3 2022 Nov 14, 2022	SELL	$1.81 - $56.1 $79 - $2,468	-44 Reduced 7.46%	546 $1,000
Q2 2022 Aug 12, 2022	SELL	$1.64 - $3.11 $48,621 - $92,202	-29,647 Reduced 98.05%	590 $2,000
Q1 2022 May 16, 2022	BUY	$2.6 - $3.3 $50,928 - $64,640	19,588 Added 183.94%	30,237 $87,000
Q4 2021 Feb 14, 2022	BUY	$3.05 - $7.08 $27,056 - $62,806	8,871 Added 498.93%	10,649 $32,000
Q3 2021 Nov 15, 2021	BUY	$6.68 - $15.26 $9,205 - $21,028	1,378 Added 344.5%	1,778 $13,000
Q2 2021 Aug 16, 2021	BUY	$7.19 - $18.96 $2,020 - $5,327	281 Added 236.13%	400 $6,000
Q1 2021 May 13, 2021	BUY	$4.4 - $8.84 $523 - $1,051	119 New	119 $1,000

564

Ticker GTBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,557,700
Market Cap $96.4M
Description
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate th...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.